Judith Carpio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Judith Carpio has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aina Oliver-Caldés
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona Barcelona Spain
15 shared publications - Anna de Daniel
Hematology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
15 shared publications - Anthony Matthew Battram
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
15 shared publications - Beatriz Martin-Antonio
Centro de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain
15 shared publications - Carlos Fernández de Larrea
Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
15 shared publications - David F. Moreno
Amyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain
15 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
BCMA and CD229 antigen expression on different target cell lines used in different experiments.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
BCMA and CD229 antigen expression on different target cell lines used in different experiments.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Percentage of PBMCs marked with FAR-RED Cell Trace dead after 24h of co-incubation with respective CAR T cells on a 1:1 ratio, normalized against dead cells from untransduced
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Percentage of PBMCs marked with FAR-RED Cell Trace dead after 24h of co-incubation with respective CAR T cells on a 1:1 ratio, normalized against dead cells from untransduced
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Measurement of the strength of interaction between monospecific and bispecific CAR T cells and MM.1S and MM.1S BCMA KO cells.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Measurement of the strength of interaction between monospecific and bispecific CAR T cells and MM.1S and MM.1S BCMA KO cells.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Clones of the K562 tumor cell line with different CD229 expression gradient
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Clones of the K562 tumor cell line with different CD229 expression gradient
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Expansion of MM.1S and MM.1S BCMA KO cells during one week of culture.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Expansion of MM.1S and MM.1S BCMA KO cells during one week of culture.